Clinical Trial Update: Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients [Phase 3]

View source ↗

Summary

This entry announces a Phase 3 clinical trial of CM336 for relapsed or refractory multiple myeloma that is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CM336 (CM336)

Snippet

Sponsor: Keymed Biosciences Co.Ltd | Conditions: Multiple Myeloma (MM) | Phase 3 | Status: NOT_YET_RECRUITING